Patient adherence in the Middle East is shaped by factors that have no parallel in European or North American pharmaceutical research: Ramadan fasting disrupting daily dosing cycles, biologic storage challenges under extreme heat, cost sensitivity driving early discontinuation in non-Gulf markets, and patient education gaps in populations managing complex chronic disease regimens. BioNixus designs and executes adherence research programmes across the GCC and wider Middle East — from pharmacy claims analysis and longitudinal patient surveys to qualitative barrier IDIs — that give pharmaceutical teams the evidence to understand, quantify, and address treatment non-adherence in local market terms.
Poor adherence in Middle East markets is not a peripheral issue — it directly compresses revenue per treated patient, reduces real-world effectiveness data available for payer negotiations, and undermines the ROI case for patient support programmes. Understanding what drives it is a launch-stage commercial priority.
Ramadan dosing modification, biologic storage compliance, cost-driven discontinuation in non-Gulf markets, and the family and social dynamics that either support or undermine long-term medication-taking behaviour.
Link MPR/PDC benchmarks to real-world outcomes data to build payer argumentation; use barrier analysis to prioritise patient support programme features; and map adherence evidence to formulary reimbursement narratives for NUPCO, DHA, and DOH submissions.
The Middle East carries one of the highest chronic disease burdens globally, with high prevalence of type 2 diabetes, hypertension, cardiovascular disease, and a growing incidence of cancer and autoimmune conditions. Yet treatment uptake and adherence rates in many of these conditions fall significantly below clinical guideline recommendations and below Western market benchmarks. The gap between epidemiological disease burden and treated patient population is commercially significant for pharmaceutical companies — it represents either market opportunity (if barriers to treatment initiation can be reduced) or commercial risk (if treated patients are discontinuing early and shrinking the revenue base).
Adherence research in the Middle East serves three strategic purposes. First, it quantifies the treated patient pool's real behaviour — how many patients prescribed a therapy are actually taking it as directed, and for how long? Second, it diagnoses the specific barriers driving non-adherence, enabling targeted intervention design. Third, it generates the real-world effectiveness data that increasingly sophisticated GCC payers — particularly NUPCO in KSA, DHA and DOH in UAE — require as part of formulary review and budget impact assessment processes. A brand that can demonstrate that its supported patient population achieves a Medication Possession Ratio of 80%+ versus a category average of 55–60% has a powerful reimbursement argument.
Adherence research is also the evidence foundation for patient support programme (PSP) ROI justification. PSPs — nurse-led support, digital coaching, adherence reminder programmes — carry significant costs. Demonstrating their adherence impact through before-and-after measurement, or through comparative cohort analysis, is increasingly required by both internal brand teams (justifying PSP budget) and external payers (who may co-invest in adherence programmes that reduce downstream hospitalisation costs).
Adherence and persistence measure different dimensions of treatment-taking behaviour and require different measurement approaches. Understanding the distinction is essential for designing a Middle East adherence programme that produces the right evidence for the intended decision.
Adherence — also called compliance in older literature — measures the degree to which a patient takes their prescribed medication as directed: correct dose, correct timing, correct frequency. Adherence is typically expressed as a ratio: Medication Possession Ratio (MPR) measures the days of medication supply dispensed divided by the days in the observation period; Proportion of Days Covered (PDC) adjusts for overlapping refills and is considered the more conservative and preferred metric. Both can be calculated from pharmacy dispensing records if claims data is available, or estimated from self-report using validated instruments such as the Morisky Medication Adherence Scale-8 (MMAS-8).
Persistence measures the duration of continuous therapy before a patient stops treatment. It is typically expressed as the proportion of patients still on therapy at 90 days, 6 months, and 12 months from initiation, or as a median time to discontinuation. Persistence measurement requires a longitudinal data source — either pharmacy claims or a prospective patient follow-up study. In GCC markets, published 12-month persistence data for chronic disease treatments typically shows rates 15–25 percentage points below European benchmarks, driven by a combination of cost, side effect tolerance, and the health belief factors described below.
A well-designed Middle East adherence programme measures both dimensions and connects them to outcomes: patients with PDC above 80% should show better clinical marker control (HbA1c for diabetes, LDL for cardiovascular, disease activity scores for autoimmune conditions) than patients with PDC below 60%, and this outcomes linkage is the core of the HEOR evidence narrative for payer-facing submissions.
Several adherence barrier categories are distinctive to Middle East markets and must be explicitly addressed in research design.
Ramadan fasting and dosing disruption. The Islamic month of Ramadan creates a predictable, annual adherence challenge for patients on daily medications. During Ramadan, observant Muslim patients fast from pre-dawn to sunset, fundamentally disrupting the dosing schedules of medications prescribed for two, three, or four times daily dosing. For diabetes medications, the interaction is particularly complex: insulin dosing requires adjustment to prevent hypoglycaemia during fasting hours; oral agents such as sulphonylureas carry hypoglycaemia risk if not timed to align with the single large Iftar meal; SGLT-2 inhibitors may increase dehydration risk during prolonged fasting. Many patients self-adjust their regimens during Ramadan without physician guidance, and some stop treatment entirely during the month. Research that does not capture Ramadan-related dosing patterns is missing a systematic adherence event that affects 100% of Muslim patients.
Heat and biologic storage compliance. Many GCC regions experience summer temperatures consistently above 40–45°C. Self-administered biologics (TNF inhibitors for RA and psoriasis, GLP-1 receptor agonists for diabetes, insulin formulations) require cold chain storage at 2–8°C. When patients transport these products from pharmacy to home, or during travel, brief temperature excursions above safe storage thresholds are common. In households without reliable refrigeration access — more prevalent in lower-income expatriate communities than in national populations — storage non-compliance may affect product efficacy. Adherence research in biologic categories should include specific cold chain and storage compliance assessment modules.
Cost sensitivity in non-Gulf Middle East markets. In Egypt, Jordan, Lebanon, and to a lesser extent in less-wealthy GCC communities, out-of-pocket drug costs drive adherence behaviour more directly than in high-income Gulf countries. For branded originators not covered by insurance, the cost barrier at refill is the primary driver of non-persistence. Research in these markets must capture the cost calculation patients make at each refill decision — whether the medication benefit justifies the out-of-pocket outlay — and where generic or cheaper alternatives are being substituted.
Patient education gaps and health belief barriers. Across Middle East markets, treatment discontinuation driven by misunderstanding of disease chronicity is a well-documented barrier. Patients with hypertension who feel well stop antihypertensive medication, believing the disease is resolved. Patients with rheumatoid arthritis stop biologic therapy during periods of low disease activity. Patients with type 2 diabetes stop oral agents when they lose weight and feel better. These gaps in understanding of treatment purpose and the concept of chronic disease management represent an educational intervention opportunity that adherence research can precisely locate and quantify.
Social and family influences on treatment-taking. As with patient journey dynamics, adherence in GCC is influenced by family context. A patient whose family is sceptical of long-term medication — possibly preferring traditional or herbal remedies — faces a social headwind that undermines pharmacist and physician counselling. Research that captures family and social influences on adherence provides the basis for designing patient support materials that engage caregivers as well as patients.
Certain therapeutic areas combine high disease burden with particularly challenging adherence profiles in Middle East markets, making them priority targets for adherence research investment.
Diabetes — oral and injectable. With type 2 diabetes prevalence among the highest globally, adherence to oral antidiabetic agents and insulin in the Middle East is a commercial and public health priority. Published research from GCC settings shows one-year PDC for metformin in the 55–65% range, substantially below the 75–80% threshold often used as a benchmark for adequate adherence. For injectable GLP-1 agonists — higher efficacy, higher cost, and more complex administration — first-year persistence rates in GCC are typically 40–55%, with a significant early drop-off in months 1–3 due to gastrointestinal side effects and injection site concerns. Adherence research in diabetes must capture both the Ramadan fasting modification pattern and the self-initiated regimen adjustment behaviour that characterises many patients managing their own glycaemic control.
Cardiovascular disease — statins and antihypertensives. Statin adherence in Middle East markets is affected by the same drivers as in other regions — side effect concerns (myalgia, liver concerns), the "feeling well" discontinuation phenomenon, and cost — but at higher rates of discontinuation. One-year statin discontinuation rates in GCC cohort studies have been reported as high as 50–60%, versus approximately 30–35% in UK general practice data. Antihypertensive adherence in KSA and Egypt is similarly below international benchmarks, with a particularly pronounced drop-off at 6 months. Research in this area maps the specific trigger events for discontinuation.
Oncology oral agents. Oral oncology therapies — tyrosine kinase inhibitors, CDK4/6 inhibitors, PARP inhibitors — require careful adherence for efficacy maintenance and have complex side effect profiles. In GCC, adherence support for oral oncology is less well developed than in European markets, and patient monitoring infrastructure outside major academic hospitals is limited. Adherence research for oral oncology products should capture the full side effect management picture and the role of oncology nurse and pharmacist touchpoints in supporting medication-taking.
Biologics for RA and psoriasis. Self-administered biologic injectables for rheumatoid arthritis and plaque psoriasis face a particular set of Middle East adherence challenges: injection anxiety, storage compliance in hot climates, cost (where insurance coverage is incomplete), and Ramadan fasting (while biologics are not typically contraindicated during Ramadan, patients sometimes self-discontinue during the holy month based on generalised concerns about medication interactions with fasting). Adherence research in this category should include a storage compliance module and Ramadan-specific adherence assessment.
Middle East adherence research programmes use a combination of methods selected to match the data availability, timeline, and evidence objective.
Pharmacy claims analysis. Dispensing records from hospital pharmacy management systems (used by major MOH hospitals and the SAMED/Aramco system in KSA) and insurance claims databases (DAMAN in Abu Dhabi, DHA-linked insurance data in Dubai) provide objective, retrospective adherence data at scale. MPR and PDC can be calculated for large patient cohorts without the cost and time of prospective patient recruitment. The primary limitation is data access — institutional partnerships must be negotiated, and de-identification and data governance processes add pre-analysis setup time (typically 2–3 months). Where claims data is available, it provides the most credible population-level adherence evidence for payer submissions.
Longitudinal patient surveys. Prospective follow-up studies with structured self-report adherence measures (MMAS-8, PDC estimation, pill diary) at baseline and multiple follow-up timepoints (90 days, 6 months, 12 months) capture adherence trajectory over time and allow statistical modelling of predictors of non-adherence. Recruiting a cohort of 200–300 newly initiated patients across two or three GCC markets requires institutional partnerships (to identify patients at treatment initiation) and a 10–14 month follow-up window for 12-month persistence data. These studies are resource-intensive but produce the most complete longitudinal adherence picture.
Cross-sectional quantitative surveys. Single-timepoint quantitative surveys with 200–500 patients using validated adherence scales provide cost-effective adherence snapshots and barrier profiling. Cross-sectional surveys cannot measure persistence directly (they capture adherence at a single moment) but are well-suited for barrier identification and segmentation analysis. For a cross-sectional survey, 300 patients across three GCC markets stratified by treatment duration (early, mid, and late treatment) can proxy the longitudinal adherence trajectory without the time investment of a prospective study.
Qualitative barrier and driver IDIs. In-depth interviews with 20–30 patients (and 10–15 caregivers) qualitatively explore the reasons behind adherence behaviour — the beliefs, experiences, and external factors that drive medication-taking decisions. Qualitative IDIs do not generate MPR or PDC statistics, but they provide the causal narrative that explains the quantitative adherence patterns and generates specific intervention hypotheses. They are typically conducted as the first phase of a mixed-method adherence programme: qualitative to generate hypotheses, quantitative to validate at scale.
Electronic medication monitoring. Smart pill bottle devices (e.g., MEMS caps) and connected packaging solutions that record each medication access event provide the most granular adherence data — exact dose timing, missed doses, and day-to-day variability. Electronic monitoring is currently used primarily in clinical trials and PSP evaluation contexts rather than standard market research, due to device cost and patient burden. However, for biologics or oral oncology products where minute-level dosing precision matters for efficacy, electronic monitoring data is a valuable addition to standard pharmacy claims or survey methods.
GCC payers — NUPCO (KSA), DHA formulary committee (Dubai), DOH formulary committee (Abu Dhabi), and Kuwait Central Medical Stores — are increasingly sophisticated in their evaluation of value evidence. Simple clinical trial efficacy data is no longer sufficient for premium formulary positioning or restricted-access classification. Payers want to understand what happens to the product's efficacy and cost-effectiveness when real patients in their population use it — and adherence data is a central component of that real-world evidence picture.
For payer-facing adherence evidence, three types of output are most valuable. First, a local MPR or PDC benchmark comparing the product to the category average — demonstrating that the product achieves higher adherence than alternatives (or providing an argument for a patient support programme to close the gap if it does not). Second, an outcomes-linked adherence analysis showing that patients with high adherence achieve better clinical outcomes (lower HbA1c, better disease control scores, fewer emergency hospitalisations) — this is the core health economics argument for formulary reimbursement. Third, a PSP impact evaluation — if a patient support programme is being co-funded or proposed for co-funding by the payer, adherence data comparing supported versus unsupported patient cohorts provides the ROI evidence for the payer's investment decision.
NUPCO in KSA is increasingly including real-world effectiveness and adherence evidence requirements in their product evaluation frameworks, particularly for specialty products (biologics, oncology agents, diabetes injectables) where cost per patient is high. DHA in Dubai has published explicit guidance on the role of health economic evidence in formulary decisions. Adherence research that is designed from the outset with payer evidence requirements in mind will produce more commercially actionable outputs than adherence research designed purely as a market research exercise.
BioNixus conducts patient adherence research across six primary Middle East markets, each with distinct data infrastructure and research context.
Saudi Arabia: The most important GCC market for adherence research. MOH hospital pharmacy data and the emerging NUPCO claims infrastructure provide claims-based adherence analysis capability. Patient survey research is conducted across Riyadh, Jeddah, and Eastern Province with Arabic-language instruments.
UAE: The most data-rich GCC market for adherence claims analysis. DAMAN (now Abu Dhabi National Insurance Company Health) and DHA insurance claims databases provide some of the best longitudinal pharmacy dispensing records in the region. UAE patient surveys are English-dominant with Arabic optional.
Egypt: The largest patient population in the region — approximately 105 million people — with high chronic disease burden and a price-sensitive pharmacy environment. Egypt is critical for understanding cost-driven non-adherence. Survey research infrastructure is well-developed; claims data is less available than Gulf markets. Egyptian Arabic is the primary language.
Kuwait: Small population but high per-capita healthcare spending and a government-subsidised medicine system. Adherence research in Kuwait benefits from a concentrated patient population in Kuwait City, but panel sizes are limited for niche specialties.
Jordan: An important market for research targeting Levantine patient populations and as a pilot market for Middle East adherence patterns in a cost-constrained environment. Jordan Arabic (a Levantine dialect) requires separate instrument adaptation from Gulf Arabic.
Lebanon: Historically a strong research market, though political and economic instability in recent years has complicated fieldwork logistics. For pharmaceutical teams with Lebanon in scope, BioNixus advises on current data collection feasibility on a study-by-study basis.
The following cost and timeline ranges are for the primary research and data analysis components of Middle East adherence programmes. Reporting and visualisation are scoped separately.
Cross-sectional quantitative adherence survey, 300–500 patients, 3 markets: $40,000–$70,000; 6–10 weeks. Qualitative barrier IDI programme, 20–30 patients + 10–15 caregivers, 2–3 markets: $45,000–$75,000; 6–10 weeks. Mixed-method programme (qualitative barriers + cross-sectional quantitative): $75,000–$120,000; 10–14 weeks. Longitudinal patient survey with 12-month follow-up, 200–300 patients, 3 markets: $100,000–$160,000; 14–18 months end-to-end. Pharmacy claims analysis (where data partnership is established), 2–3 GCC markets: $50,000–$80,000; 8–12 weeks from data access to findings. Comprehensive programme (claims analysis + longitudinal survey + barrier IDIs): $150,000–$220,000; timeline depends on claims data access and follow-up period.
Survey turnaround
6–10 weeks
Cross-sectional adherence survey across 3 Middle East markets from brief to clean data.
Cost range
$70k–$200k
Mixed-method to comprehensive adherence programme across GCC and wider Middle East.
Country coverage
6 markets
Saudi Arabia, UAE, Egypt, Kuwait, Jordan, and Lebanon with adapted Arabic instruments.
Adherence and persistence are related but distinct measures of treatment-taking behaviour. Adherence refers to the degree to which a patient takes their medication as prescribed — correct dose, correct timing, correct frequency — over a defined period. It is typically measured using the Medication Possession Ratio (MPR) or Proportion of Days Covered (PDC), both derived from pharmacy dispensing records or patient self-report. Persistence refers to the duration of continuous therapy before discontinuation — essentially, how long the patient stays on treatment before stopping. A patient can be adherent (taking the correct dose when they do take their medication) but non-persistent (stopping after 3 months). Both dimensions matter commercially: low adherence reduces real-world efficacy and generates negative HCP perceptions; low persistence directly compresses revenue per treated patient. Middle East adherence research typically measures both simultaneously.
Several adherence barriers are distinctively prevalent or intensified in Middle East contexts. Ramadan fasting is the most regionally specific barrier: Muslim patients who fast during Ramadan face significant challenges with medications prescribed for three or four daily dosing — insulin and oral diabetes agents are particularly affected, as the fasting-to-feeding pattern disrupts the glycaemic management regimen entirely. Biologic storage under Middle East heat conditions is a real barrier for self-administered injectables — heat stability of biosimilars and originator biologics during transport and home storage in environments that exceed 35°C requires patient education that is rarely provided. Cost sensitivity in non-Gulf markets (Egypt, Jordan, Lebanon) drives early discontinuation when out-of-pocket costs are high or when generic alternatives are available at pharmacy level. Patient education gaps — particularly for patients with limited health literacy — result in misunderstanding of treatment duration or purpose (for example, patients stopping antibiotic courses early once feeling better, or discontinuing statins after feeling well, believing the treatment is no longer necessary).
Adherence measurement in Middle East pharma research uses three main approaches depending on data availability and study objective. Pharmacy claims analysis uses dispensing records from hospital pharmacy systems or insurance claims databases to calculate MPR and PDC at the population level — this is the strongest method for epidemiological adherence estimates and is increasingly available in UAE (DAMAN, DHA claims) and KSA (NUPCO, MOH hospital pharmacy data) through data partnership arrangements. Longitudinal patient surveys use structured self-completion questionnaires administered at baseline and 90-day/6-month/12-month follow-up intervals to track self-reported adherence using validated instruments such as the Morisky Medication Adherence Scale (MMAS-8) or the Adherence to Refills and Medications Scale (ARMS). Pill count and electronic monitoring studies involve direct measurement of tablets returned at follow-up visits (pill count) or electronically monitored pill bottle access events — these are most commonly used in prospective studies attached to clinical practice. Each method has strengths and weaknesses: pharmacy claims are objective but don't capture adherence intent; self-report surveys are feasible but subject to social desirability bias; electronic monitoring is most accurate but most expensive and logistically intensive.
Ramadan has two types of impact on adherence research: it creates a real adherence event (patients modifying dosing patterns during the holy month), and it affects research operations (patient availability is reduced, clinic hours are shorter, and self-completion survey response rates drop during fasting hours). For adherence studies in Middle East markets, Ramadan should be treated as a dedicated measurement window rather than noise to be avoided. Studies with a longitudinal follow-up component should build Ramadan assessment into the protocol if the follow-up window overlaps with the holy month — capturing what patients actually do with their medication during Ramadan (dose skipping, timing modification, complete cessation) is a critical commercial insight for products with complex dosing schedules. Conversely, studies that need stable baseline adherence measurement without Ramadan interference should schedule baseline assessment at least 4–6 weeks after Eid ul-Fitr. BioNixus advises on Ramadan scheduling implications at study design stage.
Adherence data strengthens formulary and reimbursement arguments in two ways. First, it demonstrates real-world efficacy — payers in GCC (NUPCO, DHA formulary committee, DOH Abu Dhabi) are increasingly asking for real-world evidence that a product's clinical trial efficacy translates into outcomes in the local patient population. Adherence is a proxy for real-world effectiveness: a treatment that patients actually take consistently delivers better outcomes than a theoretically superior treatment that patients discontinue early. Second, adherence data quantifies the cost-effectiveness of patient support programmes — if a structured nurse-support or digital coaching programme raises PDC from 55% to 75% in an injectable biologic, the incremental cost of the programme can be modelled against the reduction in disease exacerbations or hospitalisations. This HEOR narrative is increasingly effective in GCC payer discussions, particularly in the UAE and KSA where health economics capacity is growing.
Cost and timeline depend heavily on the measurement approach. A cross-sectional quantitative adherence survey (300–500 patients, self-report via validated scale, two or three GCC markets) costs $40,000–$70,000 and takes 6–10 weeks from brief to clean data. A longitudinal adherence study with baseline and two follow-up assessments at 90 days and 12 months (200–300 patients, three markets) costs $90,000–$140,000 and takes 14–18 months end-to-end (though early interim data may be available from 4–6 months). A pharmacy claims-based adherence analysis using insurance or hospital pharmacy data (where data partnership access is already established) costs $50,000–$80,000 and takes 8–12 weeks for analysis and reporting, but may require 2–3 months of partnership arrangement time before data access is granted. A comprehensive adherence programme combining pharmacy claims analysis, longitudinal patient survey, and barrier IDIs runs $120,000–$200,000 over a 10–16 week timeline for the primary research component.